Portal de investigación
- Inicio
- Proyectos y Estudios
- ESTUDIO OBSERVACIONAL PARA EVALUAR LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO CON BENDAMUSTINA ASOCIADA A RITUXIMAB EN PACIENTES AFECTOS DE LEUCEMIA LINFÁTICA CRÓNICA. AN OBSERVATIONAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF BENDAMUSTINE PLUS RITUXIMAB I N PATIENTS AFFECTED BY CHRONIC LYMPHOCYTIC LEUKEMIA.
ESTUDIO OBSERVACIONAL PARA EVALUAR LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO CON BENDAMUSTINA ASOCIADA A RITUXIMAB EN PACIENTES AFECTOS DE LEUCEMIA LINFÁTICA CRÓNICA. AN OBSERVATIONAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF BENDAMUSTINE PLUS RITUXIMAB I N PATIENTS AFFECTED BY CHRONIC LYMPHOCYTIC LEUKEMIA.
Datos básicos
- Código:
- GIM-RIT-2016-01
- Protocolo:
- GIM-RIT-2016-01
- EUDRACT:
- NCT:
- Centro:
- Dotación:
- Año de incio:
- Año de finalización:
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients.
Lozano ML; (...); Vicente V
Article. 10.1016/j.bcmd.2020.102505. 2021
A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study)
Vallejo C; (...); Codesido ML
Article. 10.1007/s00277-023-05602-x. 2024
A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Lopez-Guillermo, Armando; (...); Tomas, Jose Francisco
Article. 10.1080/10428194.2021.1971216. 2021
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Encinas, Cristina; (...); Martinez-Lopez, Joaquin
Article. 10.1038/s41408-022-00652-2. 2022
Accuracy and prognostic impact of FDG PET/CT and biopsyin bone marrow assessment of follicular lymphomaat diagnosis: A Nation-Wide cohort study.
Rodenas-Quinonero, Isabel; (...); Ortuno, Francisco Jose
Article. 10.1002/cam4.5424. 2022
Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review
Review. 10.1177/20406207211038181. 2021
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice
Stadtmauer, Edward A.; (...); ZOE-SCT Study Grp Collaborators
Article. 10.1080/21645515.2021.1953346. 2021
Allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma. Impact of disease characteristics, disease status at transplant, and prior number of lines of therapy. Results of retrospective, multicentre Spanish study
De la Rubia, J; (...); Gonzalez, MS
Meeting Abstract. 2019
ANALYSIS OF PROGRESSION-FREE SURVIVAL OF AND GLOBAL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA OLDER THAN 65 YEARS CANDIDATES FOR AUTOLOGOUS PERIPHERAL BLOOD TRANSPLANTATION NON-CANDIDATES
Cejalvo, MJ; (...); De la Rubia, J
Meeting Abstract. 2017
Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype
Ibanez, M; (...); Cervera, J
Article. 10.1038/s41598-020-61589-9. 2020
ANALYSIS OF THE CLINICAL EVOLUTION OF PATIENTS WHO UNDERWENT A SECOND AUTOTRANSPLANTATION OF PERIPHERAL BLOOD FOR RELAPSED MULTIPLE MYELOMA
Garcia, Ruiz Raquel; (...); Arnao, Herraiz Mario
Meeting Abstract. 2020
ANALYSIS OF THE PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ELDERLY PATIENTS (65 YEARS OLD) WITH MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION.
Cejalvo, MJ; (...); De la Rubia J
Meeting Abstract. 2018
Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study.
de la Asunción CS; (...); Navarro D
Article. 10.1002/jmv.28933. 2023
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
Casanova, B; (...); Coret, F
Article. 10.1007/s10072-017-2933-6. 2017
Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
García-Sancho AM; (...); Caballero D
Article. 10.3324/haematol.2021.279426. 2022
Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure
Jiménez-Ubieto A; (...); Lahuerta JJ
Article. 10.1016/j.bbmt.2017.05.021. 2017
Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment
Jimenez-Ubieto, A; (...); GELTAMO Grp Espanol Linfomas Tr
Article. 10.1002/hon.2553. 2018
Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy.
Jiménez-Ubieto A; (...); GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Stu
Article. 10.1016/j.hemonc.2019.06.001. 2019
Autologous Stem Cell Transplantation may potentially abrogate the negative prognostic effect of early relapse after chemo or inmunochemotherapy in Follicular Lymphoma
Ubieto, AJ; (...); Lahuerta, JJ
Meeting Abstract. 2018
AUTONOMOUS TRANSPLANTATION CAN MITIGATE THE ADVERSE PROGNOSIS OF THE EARLY RELAPSE AFTER CHEMO OR IMMUNOCHEMOTHERAPY INDUCTION IN FOLLICULAR LYMPHOMA
Ubieto, AJ; (...); Lahuerta, J. J.
Meeting Abstract. 2017
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI).
Pascual-Izquierdo C; (...); Mingot-Castellano ME
Article. 10.1002/ajh.27498. 2024
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
Redondo, AM; (...); GEL-TAMO
Article. 10.1111/bjh.15713. 2019
Bendamustine plus rituximab in untreated chronic lymphocytic leukemia patients. The MDA-CLL-2015-02 study
De La Fuente, A; (...); Baltasar, P
Meeting Abstract. 2017
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma.
Rosiñol L; (...); Bladé J
Article. 10.1182/blood.2019000241. 2019
Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2020.12.019. 2021
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country.
Muntañola A; (...); Bosch F
Letter. 10.1186/s40164-020-00195-x. 2020
Clinical Characteristics and Transfusion Management of Patients Diagnosed of Multiple Myeloma Receiving Daratumumab: Experience of a Single Centre
Arnao, M; (...); Sanz, G
Meeting Abstract. 10.1016/j.clml.2019.09.254. 2019
Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing
Ibanez, Mariam; (...); Cervera, Jose
Meeting Abstract. 10.1182/blood.V128.22.598.598. 2016
COMPARATIVE STUDY OF THE CLINICAL-BIOLOGICAL CHARACTERISTICS TO THE DIAGNOSIS AND RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA
Valenzuela, AV; (...); Ramos, IJ
Meeting Abstract. 2018
Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation
Article. 10.1111/ejh.13270. 2019
Considering Bone Marrow Blasts from Nonerythroid Cells Improves the Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts
Arenillas, Leonor; (...); Florensa, Lourdes
Meeting Abstract. 2016
Considering Bone Marrow Blasts from Nonerythroid Cellularity Improves the Prognostic Evaluation of MDS in the Context of IPSS-R and Permits a Better Risk Assessment of MDS Patients Classified into the Intermediate Risk Category
Calvo, Xavier; (...); Florensa, Lourdes
Meeting Abstract. 10.1182/blood.V128.22.3185.3185. 2016
Copper deficiency: a cause of misdiagnosis of myelodysplastic syndrome
Villalba, A; (...); Senent, L
Letter. 10.1007/s00277-018-3334-5. 2018
COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA
Gironella, M.; (...); Oyaguez, I
Meeting Abstract. 2019
Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia
Casado, LF; (...); Castro, A
Article. 10.1111/ejh.13007. 2018
COST-UTILITY OF IDELALISIB IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Casado, LF; (...); Castro-Gomez, A
Meeting Abstract. 10.1016/j.jval.2017.08.898. 2017
CRITICAL REVIEW OF THE DOUBLE NEGATIVITY IN THE SERUM AND URINE IMMUNOFIXATION (IF) TO ESTABLISH THE CATEGORY OF COMPLETE REMISSION IN MULTIPLE MYELOMA (MM)
Anglada, LL; (...); Lahuerta, J. J.
Meeting Abstract. 2017
Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis.
Puerta-Alcalde, Pedro; (...); Garcia-Vidal, Carolina
Article. 10.1093/mmy/myac038. 2022
Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
Solano de la Asuncion, Carlos; (...); Navarro, David
Letter. 10.1111/bjh.17732. 2021
Cytotoxic Natural Killer Subpopulations as a Prognostic Factor of Malignant Pleural Effusion
Lara, SH; (...); Suarez-Varela, MM
Article. 10.1007/s00408-018-0186-7. 2019
Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing.
Calleja-Panero, Jose Luis; (...); Gonzalez Calvo, Jose
Article. 10.1016/j.gastrohep.2023.05.010. 2023
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (vol 11, 16867, 2021)
Lozano, Maria L.; (...); Vicente, Vicente
Article. 10.1038/s41598-021-95732-x. 2021
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
Lozano ML; (...); Vicente V
Article. 10.1038/s41598-019-53209-y. 2019
Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review.
Mansilla-Polo M; (...); Botella-Estrada R
Letter. 10.1111/ddg.15502. 2024
DETERMINATION OF THE CHALLENGES AND OPPORTUNITIES ASSOCIATED WITH PLATELET TRANSFUSION IN THE MANAGEMENT OF PATIENTS WITH SEVERE THROMBOCYTOPENIA ASSOCIATED WITH CHRONIC LIVER DISEASE
Jarque, Ramos, I; (...); Shepherd, Moreno J.
Meeting Abstract. 2020
DETERMINING THE EPIDEMIOLOGY, PATIENT FLOW, TREATMENT AND UNMET NEEDS OF PATIENTS WITH CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA UNDERGOING INVASIVE PROCEDURES IN SPAIN
Andrade, R.; (...); Shepherd, J.
Meeting Abstract. 2019
DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN
Poveda, J. L.; (...); Vitoria, I
Meeting Abstract. 2019
Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain
Badia, X; (...); Poved, JL
Article. 10.1080/21678707.2019.1652163. 2019
Do Guidelines Influence Diagnostic and Therapeutic Practice in Immune Thrombocytopenia? Results of a Multicenter Retrospective Study
Luisa Lozano, Maria; (...); Vicente Garcia, Vicente
Meeting Abstract. 10.1182/blood-2019-125557. 2019
Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant
Solano C; (...); Bow EJ
Article. 10.1111/myc.12552. 2017
Editorial: Infectious diseases and hematology: diagnosis and management
Gonzalez-Lopez, Tomas Jose; (...); Di Micco, Pierpaolo
Editorial Material. 10.3389/fmed.2024.1385874. 2024
EFFECT OF PREGNANCY IN THE CLINICAL COURSE OF PREGNANT WOMEN WITH PTI AND THEIR OFFSPRING. RESULTS OF A SERIES OF SPANISH CASES WITH 263 PREGNANCIES IN PRIMARY PTI
Lopez, TJG; (...); Hermida, G.
Meeting Abstract. 2017
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial
Bastidas, A; (...); ZOE-HSCT Study Grp Collaborators
Article. 10.1001/jama.2019.9053. 2019
Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study
Ferra, Christelle; (...); Baltasar, Patricia
Meeting Abstract. 10.1182/blood-2022-162186. 2022
Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real World Setting in Spain: The Venares Study
Baltasar, Patricia; (...); Ferra, Christelle
Meeting Abstract. 10.1182/blood-2021-147685. 2021
EFFICACY OF IBRUTINIB IN THE TREATMENT OF LINFOPROLIFERATIVE SYNDROMES: EXPERIENCE IN REAL LIFE OF THE VALENCIAN COMMUNITY
Martin, EMD; (...); Castera, MJT
Meeting Abstract. 2018
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Peffault de Latour R; (...); Risitano AM
Article. 10.1056/NEJMoa2109965. 2022
ELTROMBOPAG ADDED TO STANDARD IMMUNOSUPPRESSION IMPROVES RESPONSE RATE IN SEVERE APLASTIC ANEMIA: RESULTS OF THE MULTICENTER PHASE III PROSPECTIVE RANDOMIZED RACE TRIAL
Risitano, A. M.; (...); de latour, R. Peffault
Meeting Abstract. 2021
ELTROMBOPAG ADDED TO STANDARD IST IS SUPERIOR TO IST ALONE AS FRONT-LINE TREATMENT FOR SEVERE APLASTIC ANEMIA: FINAL 2-YEAR ANALYSIS OF EBMT-SAAWP RACE STUDY
Risitano, Antonio Maria; (...); de Latour, Regis Peffault
Meeting Abstract. 2024
Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Meeting Abstract. 10.1182/blood-2023-180691. 2023
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies.
Gudiol C; (...); de la Cámara R
Article. 10.1016/j.eimc.2019.01.013. 2020
Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Ayyappan, Sabarish; (...); Prince, H. Miles
Meeting Abstract. 10.1182/blood-2023-179818. 2023
Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.
Gonzalez-Lopez, Tomas Jose; (...); Garcia-Donas Gabaldon, Gloria
Article. 10.1182/blood.2024024250. 2024
Frequency, characteristics and outcomes of Lymphoproliferative Disorders After Allogeneic Stem Cell Transplant: results of a multicenter study from the Grupo Espanol de Trasplante Hematopoyetico (GETH)
Garcia Cadenas, Irene; (...); Solano, Carlos
Meeting Abstract. 2018
Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)
Garcia-Cadenas, I; (...); Spanish Grp Blood & Marrow Tran
Article. 10.1111/ejh.13226. 2019
Further psychometric validation of the GAH scale: Responsiveness and effect size
Cruz-Jentoft, AJ; (...); GAH Group
Article. 10.1016/j.jgo.2016.12.008. 2017
GAH SCALE PREDICTS TREATMENT TOLERABILITY IN OLDER PATIENTS (> 65 YEARS) DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES
Bonanad, S; (...); de la Rubia, J
Meeting Abstract. 2017
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
de la Rubia J; (...); Bonanad, Santiago
Article. 10.1016/j.jgo.2022.10.016. 2022
GUIDELINES OF PRESCRIPTION IN FIRST LINE OF PATIENTS WITH MULTIPLE MYELOMA NOT CANDIDATES TO TRANSPLANTATION STRATIFIED BY AGE IN REAL LIFE IN SPAIN BETWEEN 2012 AND 2016
Cejalvo, M. J.; (...); Sarra, J.
Meeting Abstract. 2019
Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study
Iskierka-Jazdzewska, Elzbieta; (...); Ivanescu, Cristina
Meeting Abstract. 10.1182/blood-2023-180743. 2023
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance
Garcia-Marco, JA; (...); GELLC Study Grp
Article. 10.3324/haematol.2018.204891. 2019
Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).
Abrisqueta, Pau; (...); Bosch, Francesc
Article. 10.1016/j.eclinm.2024.102642. 2024
IBRUTINIB IN COMBINATION WITH R-GEMOX-D IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN RECALLING OR REFRACTORY: PHASE II STUDY OF THE GELTAMO GROUP
Rey, Bua Beatriz; (...); Martin, A.
Meeting Abstract. 2020
IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients.
Vallejo, Carlos; (...); Peman, Javier
Article. 10.3390/jof9060628. 2023
IMMUNE THROMBOCYTOPENIA AND PREGNANCY: A SPANISH CASE SERIES OF 270 PREGNANCIES IN PRIMARY ITP.
Gonzalez-Lopez, TJ; (...); Porras, JRG
Meeting Abstract. 2017
Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors.
de la Asuncion Carlos, Solano; (...); Navarro, David
Letter. 10.1111/bjh.18655. 2023
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.
Lakhwani S; (...); Hernández MT
Article. 10.1007/s00277-024-06031-0. 2024
Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-166826. 2022
Immunotherapy in multiple myeloma.
Asensi Cantó P, Arnao Herraiz M, de la Rubia Comos J
Article. 10.1016/j.medcli.2023.11.019. 2024
IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)
Ibanez, Mariam; (...); Sanz, Guillermo
Meeting Abstract. 2020
INCIDENCE AND CHARACTERISTICS OF POST-TRANSPLANT ALLOGENIC LYMPHOPROLIFERATIVE SYNDROMES. EXPERIENCE OF SPANISH GROUP OF HEMATOPOIETIC TRANSPLANT (GETH)
San Segundo, LY; (...); Solano, C.
Meeting Abstract. 2017
Incidence and Management of Aplastic Anemia in Spain (IMAS). An Ambispective Study of Biodonostia / Pethema
Vallejo, C; (...); Jarque, I
Meeting Abstract. 2020
Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
Rodríguez-Veiga R; (...); Sanz GF
Article. 10.1007/s00277-019-03744-5. 2019
Infections of the Central Nervous System after Untelated Donor Umbilical Cord Blood Transplantation or Human teukocyte Antigen-Matched Sibling Transplantation
Balaguer Rosello A; (...); Sanz, J
Article. 10.1016/j.bbmt.2016.10.005. 2017
Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study
Luisa Lozano, Maria; (...); Vicente Garcia, Vicente
Meeting Abstract. 10.1182/blood-2019-122237. 2019
Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial
Rosinol, Laura; (...); Blade Creixenti, Joan
Meeting Abstract. 10.1182/blood-2021-146798. 2021
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Rosinol, Laura; (...); Blade, Joan
Article. 10.1182/blood.2022019531. 2023
LENALIDOMIDE IN COMBINATION WITH R-ESHAP IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMAS (DLBCL) REFRACTORY OR IN RELAPSE: STUDY PHASE 2 OF THE GELTAMO SPANISH GROUP
Baile, M.; (...); Martin, A. A.
Meeting Abstract. 2017
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.
Martin Garcia-Sancho, A.; (...); Caballero, D.
Article. 10.1111/bjh.18989. 2023
Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab
Marco-Ayala, J; (...); Peris, MLS
Editorial Material. 10.5045/br.2020.2020059. 2020
Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers
Jose Gonzalez-Lopez, Tomas; (...); Sanz, Miguel A.
Meeting Abstract. 10.1182/blood-2019-129274. 2019
Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group.
Mingot-Castellano ME; (...); González Porras JR
Article. 10.1155/2019/4621416. 2019
Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts
Calleja-Panero, JL; (...); Gil, A
Article. 10.17235/reed.2020.6895/2020. 2020
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
Richardson PG; (...); Bahlis NJ
Article. 10.1056/NEJMoa2303194. 2023
Multi- Omics Exploration of Adaptive Mechanism to BTK Inhibition By Ibrutinib in CLL Identified TMBIM6/BI-1 As a Poor Prognosis Variable and Potential Therapeutic Target
Medina, Daniel; (...); Crespo, Marta
Meeting Abstract. 10.1182/blood-2023-185683. 2023
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Kim, Won-Seog; (...); Walewski, Jan
Meeting Abstract. 10.1182/blood-2022-158406. 2022
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
Cabrero M; (...); Caballero D
Article. 10.1038/s41409-023-02171-5. 2024
Ofatumumab as Part of Reduced Intensity Conditioning in High Risk b-cell Lymphoma Patients: Results from a Prospective Multicenter Phase-II Trial
Cabrero, M; (...); Caballero, D
Meeting Abstract. 2020
Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients
Ibanez, Mariam; (...); Luna I
Article. 10.3390/diagnostics12040953. 2022
Paradoxical Findings in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors: Suboptimal Disease Control Perceived As Satisfactory
Gaya, Anna; (...); Vallejo, Carlos
Meeting Abstract. 10.1182/blood-2023-185939. 2023
Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia.
Sanz J; (...); Piñana JL
Article. 10.1016/j.bbmt.2019.08.020. 2020
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
Robak, T; (...); Jolles, S
Article. 10.1182/bloodadvances.2020002003. 2020
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Cabrero, M; (...); Caballero, D
Article. 10.1016/j.bbmt.2016.10.003. 2017
Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
Article. 10.1080/10428194.2018.1474462. 2019
Practical guide to emergency treatment of thrombotic microangiopathy
Romero S; (...); Grupo de Microangiopatía Trombótica del Hospital Universitario y Politécnico La
Editorial Material. 10.1016/j.medcli.2018.01.013. 2018
Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters
Herrera Lara S; (...); Morales Suárez-Varela M
Article. 10.1007/s00408-017-0032-3. 2017
Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up
Luisa Lozano, Maria; (...); Vicente Garcia, Vicente
Meeting Abstract. 10.1182/blood-2019-125580. 2019
PREDICTORS OF TREATMENT FREE RESPONSES WITH THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH PTI
Lozano Almela, M. L.; (...); Vicente, V.
Meeting Abstract. 2019
Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)
Abrisqueta, Pau; (...); Bosch, Francesc
Meeting Abstract. 10.1182/blood-2019-128470. 2019
Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry
Villegas, A; (...); Urbano, A
Article. 10.1007/s00277-017-3059-x. 2017
Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.
Gonzalez-Lopez, Tomas Jose; (...); Fernandez-Fuertes, Fernando
Article. 10.1016/j.blre.2023.101112. 2023
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.
Tamariz-Amador, Luis-Esteban; (...); Troconiz, Inaki F.
Article. 10.1016/j.clml.2022.04.024. 2022
Progression-free survival at 2years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma
Jimenez-Ubieto, A; (...); GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) cooperative stu
Article. 10.1002/cam4.1217. 2017
Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus.
Gonzalez-Lopez, Tomas Jose; (...); Jarque, Isidro
Article. 10.1080/09537104.2024.2336104. 2024
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Abrisqueta, Pau; (...); Villanueva, Miguel
Article. 10.1016/j.clml.2021.07.022. 2021
Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI).
Mingot-Castellano, Maria Eva; (...); Pascual-Izquierdo, Cristina
Article. 10.3390/jcm12206422. 2023
Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-167247. 2022
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Lakhwani S; (...); Hernández MT
Article. 10.3324/haematol.2023.284154. 2024
Relevancia de la anfotericina B liposomal en el tratamiento de las infecciones fúngicas invasoras en pacientes oncohematológicos.
García-Vidal C, Vázquez L, Jarque I
Article. 10.1016/j.riam.2021.03.001. 2021
RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group.
Bastos-Oreiro M; (...); López-Guillermo A
Article. 10.1007/s00277-020-03918-6. 2020
Results of the Ebmt Saawp Phase III Prospective Randomized Multicenter Race Study of Horse Atg and Ciclosporin with or Without Eltrombopag in Naive Saa Patients
de Latour, RP; (...); Risitano, A
Meeting Abstract. 2020
RESULTS OF THE PEGASUS PHASE III TRIAL FOR THE COMPARISON OF PEGCETACOPLAN WITH ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Jarque, Isidro; (...); Peffault, de latour Regis
Meeting Abstract. 2020
RETROSPECTIVE CONTROL CASE STUDY ON THE EFFICACY OF AUTOLOGOUS TRANSPLANTATION OF HAEMATOPOIETIC PROGENITORS IN THE FIRST LINE TREATMENT OF PATIENTS WITH PERIPHERAL T CELL LYMPHOMA
Parra, ML; (...); Martin, A. A.
Meeting Abstract. 2017
Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia
Robak, Tadeusz; (...); Jolles, Stephen
Meeting Abstract. 10.1182/blood-2019-129839. 2019
Safety and efficacy of the BCR inhibitors after allogeneic stem cell transplantation for CLL
Yanez, L; (...); Bosch, F
Meeting Abstract. 2019
Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry
Jimenez-Ubieto, A; (...); Lahuerta, JJ
Letter. 10.1038/s41409-018-0096-6. 2018
Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option
Roman, E; (...); Gorriz, JL
Review. 10.1016/j.nefro.2017.01.006. 2017
Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease
Lakhwani, Sunil; (...); Teodoro Hernandez Garcia, Miguel
Meeting Abstract. 10.1182/blood-2023-179452. 2023
THE LASTING RESPONSE OF ELTROMBOPAG IN PRIMARY PTI IS A PREDICTOR FOR THE PROBABILITY OF DISCONTINUING THE SUCCESS OF ELTROMBOPAG
Porras, JRG; (...); Bastida, J. M.
Meeting Abstract. 2017
The Value of Bone Marrow Assessment by FDG PET/CT, Biopsy and Aspirate in the Upfront Evaluation of Mantle Cell Lymphoma: A Nationwide Cohort Study
Quinonero, Isabel Rodenas; (...); Ortuno, Francisco Jose
Article. 10.3390/cancers16244189. 2024
THROMBOTIC EVENTS IN PATIENTS WITH PTI TREATED WITH THROMBOPOIETIN RECEPTOR AGONISTS. IDENTIFICATION OF PREDISPOSING FACTORS
Lozano Almela, M. L.; (...); Vicente, V.
Meeting Abstract. 2019
Transfusion management in multiple myeloma patients receiving daratumumab: Experience of a single tertiary care centre.
Solves P; (...); Carpio N
Article. 10.1016/j.transci.2019.09.011. 2020
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma
Cejalvo, MJ; (...); de la Rubia, J
Article. 10.1007/s00277-021-04529-5. 2021
Update of the Grupo Espanol de Leucemia Linfocitica Cronica clinical guidelines of the management of chronic lymphocytic leukemia
Garcia-Marco, JA; (...); Bosch, F
Editorial Material. 10.1016/j.medcli.2016.12.030. 2017
Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bua, BR; (...); Garcia-Sancho, AM
Meeting Abstract. 2021
Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.
González-López TJ; (...); García-Frade LJ
Article. 10.1111/ejh.13370. 2020
Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients
Rodriguez-Veiga, Rebeca; (...); Sanz, Miguel A.
Article. 10.1111/myc.12891. 2019
VALIDATION OF DIFFERENT SYSTEMS OF STRATIFICATION OF PROGNOSIS OF SMD IN AN INDEPENDENT SERIES
Collado Jose, Esteban; (...); Sanz, Guillermo
Meeting Abstract. 2016
VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study
Dachs, LR; (...); Blade, J
Meeting Abstract. 10.1182/blood-2018-99-111924. 2018